Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | CCR5 | P51681 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.49 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109981 | 0.86 | FFAR1 (0.56) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL20755877 | 0.85 | FFAR1 (0.57) | MAOBFFAR1 | |
| SCHEMBL368071 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL31644088 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL4434864 | 0.82 | SLC6A4 (0.56) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL23263356 | 0.81 | PTPN1 (0.49) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL16293828 | 0.80 | CCR5 (0.51) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL19814058 | 0.79 | MAPT (0.53) | MAOBHTTSMN1; SMN2FFAR1PTGER1 | |
| SCHEMBL15197125 | 0.79 | CCR5 (0.54) | SLC6A4MAOBCCR5ALDH1A1USP28 | |
| SCHEMBL544346 | 0.79 | SLC6A4 (0.54) | SLC6A4MAOBCCR5ALDH1A1USP28 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-11-23 | — | — | US | disclosed |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-05-06 | — | — | US | disclosed |
| EP-3744713-A1 | DIYHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | Japan Tobacco Inc. (JP) | 2020-12-02 | — | — | EP | disclosed |
| CN-107001286-B | Dihydropyrimidine-2-one compounds and medicinal use thereof | 日本烟草产业株式会社 | 2020-07-07 | — | — | CN | disclosed |
| EP-3231793-B1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | JAPAN TOBACCO INC. (JP) | 2019-02-05 | — | — | US | disclosed |
| EP-2990424-B1 | POLYMERIZABLE COMPOUND AND POLYMERIZABLE COMPOSITION | JNC CORP (JP) | 2019-01-30 | — | — | EP | disclosed |
| EP-3327045-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2018-05-30 | — | — | EP | disclosed |
| EP-3231793-A1 | DIHYDROPYRIMIDINE-2-ONE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2017-10-18 | — | — | EP | disclosed |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2016-07-07 | — | — | US | disclosed |
| US-20160075950-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-03-17 | — | — | US | disclosed |
| EP-2990424-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC Corporation (JP) | 2016-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075950-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | PYM1, DRD1, PLD1 | SLC6A4 2949/4885MAOB 3867/4885CCR5 1241/4885 |
| US-10196363-B2 | Dihydropyrimidin-2-one compounds and medical use thereof | REN, PKD2, ALPI | SLC6A4 420/4885MAOB 2640/4885CCR5 2845/4885 |
| US-20160194290-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | SLC6A4 420/4885MAOB 2640/4885CCR5 2845/4885 |
| US-20210130300-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | SLC6A4 420/4885MAOB 2640/4885CCR5 2845/4885 |
| US-20230373932-A1 | DIHYDROPYRIMIDIN-2-ONE COMPOUNDS AND MEDICAL USE THEREOF | REN, PKD2, ALPI | SLC6A4 420/4885MAOB 2640/4885CCR5 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.